Hepatitis B Vaccine Market Size Is Projected To Grow USD 10.62 Billion By 2030

Global Hepatitis B Vaccine Market 2023-2030, report discovers comprehensive insights on key manufacturers with share information, market size and projection, key dynamics, growth factors, and new company profiles. The report provides detailed information about the market overview, prevalent trends, demand, and recent developments impacting the market growth in the coming years. Hepatitis B Vaccine Market opportunities analysis, strategic growth analysis, product launches, marketplace expanding, and technological innovations are also highlighted. The report uncovers Hepatitis B Vaccine market size, potential growth, trends and expansion strategies followed by top prominent players.

The Hepatitis B Vaccine Market Size Was Valued At USD 7.53 Billion In 2021. The Market Is Projected To Grow From USD 7.80 Billion In 2022 To USD 10.62 Billion By 2030, Exhibiting a CAGR Of 4.5% During The Forecast Period.

𝗚𝗲𝘁 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙 𝗖𝗼𝗽𝘆 𝗼𝗳 𝗟𝗮𝘁𝗲𝘀𝘁 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗻 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 2023 𝗕𝗲𝗳𝗼𝗿𝗲 𝗣𝘂𝗿𝗰𝗵𝗮𝘀𝗲:
https://www.contrivedatuminsights.com/request-sample/248514

The COVID-19 pandemic has been shocking and has never happened before. Demand for the hepatitis B vaccine is lower than expected in all areas compared to levels before the pandemic. According to our research, the global market for hepatitis B vaccines will be 11.0% smaller in 2020 than it was in 2019.
Hepatitis B Virus (HBV) is a major cause of cirrhosis, chronic hepatitis, and hepatocellular cancer. It is a serious threat to people's health all over the world. There have been a lot more cases of hepatitis B because infected mothers pass it on to their babies at birth or because babies come in contact with an infected person's body fluids (such as blood or saliva).

𝗦𝗼𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗸𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝗱 𝗶𝗻 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 𝗮𝗿𝗲
GSK plc (U.K.), DYNAVAX TECHNOLOGIES CORPORATION (U.S.), VBI Vaccines Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Beijing Minhai Biological Technology Co., Ltd. (China), Gilead Sciences, Inc. (U.S.), Beijing Tiantan Biological Products Co., Ltd. (China), Amy Vaccine Co., Ltd. (China), Shenzhen Kangtai Biological Products (China), and Others.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

By Type:
• Single Antigen
• Combination
• Others

By Distribution Channel:
• Hospitals
• Government Suppliers
• Others

𝗚𝗲𝗼𝗴𝗿𝗮𝗽𝗵𝗶𝗰𝗮𝗹𝗹𝘆, 𝘁𝗵𝗲 𝗱𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗼𝗳 𝗰𝗼𝗻𝘀𝘂𝗺𝗽𝘁𝗶𝗼𝗻, 𝗿𝗲𝘃𝗲𝗻𝘂𝗲, 𝗺𝗮𝗿𝗸𝗲𝘁 𝘀𝗵𝗮𝗿𝗲 𝗮𝗻𝗱 𝗴𝗿𝗼𝘄𝘁𝗵 𝗿𝗮𝘁𝗲, 𝗵𝗶𝘀𝘁𝗼𝗿𝗶𝗰 𝗮𝗻𝗱 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝘀 (2023-2030) 𝗼𝗳 𝘁𝗵𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗿𝗲𝗴𝗶𝗼𝗻𝘀 𝗮𝗿𝗲 𝗰𝗼𝘃𝗲𝗿𝗲𝗱:
• North America (U.S., Canada)
• Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
• South America (Mexico, Brazil, Argentina, Columbia, Rest of South America)
• Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:
The North American market was worth USD 2.60 billion in 2021, and it is expected to stay the biggest market in the world for the rest of the forecast period. Hepatitis B diseases are becoming more common, and national health organisations have taken steps to prevent them, test for them, and lower the number of people who die from them. North America, which has the largest share of the world market, has been most affected by this. North America's market is also growing because more companies are teaming up and getting approval for more combination vaccines. Many people in the area use these vaccines.
Sanofi Pasteur and Merck & Co., Inc. worked together to bring Vaxelis to the U.S. in June 2021. It was the first vaccine that protects children and babies from diseases like diphtheria, tetanus, polio, Haemophilus influenzae type B (Hib), and hepatitis B.
Europe is the second most important area in terms of sales and market share. European government officials set up a number of regional action plans to protect more newborn babies from getting hepatitis B. This is why the European market held a large share. For example, the World Health Organization says that by December 2019, 50 out of 53 European countries will offer routine hepatitis B vaccinations to all infants and children ages 1-12. This includes 23 countries that give all newborns a dose of hepatitis B at birth.
Asia-share The growing number of people with hepatitis B disease is driving Pacific's share of the hepatitis B vaccine market. At the same time, companies that make vaccines are trying to raise money and work together to make new hepatitis B vaccines, which are expected to help the region grow at the highest CAGR over the next few years. In April 2022, for example, Shionogi & Co., Ltd., a Japanese pharmaceutical company that focuses on research, worked with NEC Corporation to study and make a new hepatitis B vaccine. The goal of the collaboration is to find a cure for hepatitis B and meet all of the disease's medical needs.
On the other hand, the Rest of the World (RoW) market, which includes Latin America and the Middle East, is likely to grow more slowly. Because more people in the area have hepatitis B and different strategic frameworks are being used, the market is growing faster there.

𝗧𝗼 𝗚𝗲𝘁 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗔𝗰𝗰𝗲𝘀𝘀 𝗢𝗳 𝗧𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗹𝗶𝗰𝗸 𝗛𝗲𝗿𝗲:
https://www.contrivedatuminsights.com/buy/248514

𝗧𝗮𝗯𝗹𝗲 𝗼𝗳 𝗖𝗼𝗻𝘁𝗲𝗻𝘁:
1. Executive Summary
2. Research Methodology
3. Market Outlook
4. Covid-19 Impact On Hepatitis B Vaccine Market
5. Hepatitis B Vaccine Market Overview, By Segmentation, 2017 - 2030 (USD Million)
6. Hepatitis B Vaccine Market Overview, By Geography, 2017 - 2030 (USD Million)
7. North America Hepatitis B Vaccine Market Overview, By Countries, 2017 - 2030 (USD Million)
8. Europe Hepatitis B Vaccine Market Overview, By Countries, 2017 - 2030 (USD Million)
9. Asia Pacific Hepatitis B Vaccine Market Overview, By Countries, 2017 - 2030 (USD Million)
10. Middle East & Africa Hepatitis B Vaccine Market Overview, By Countries, 2017 - 2030 (USD Million)
11. South America Hepatitis B Vaccine Market Overview, By Countries, 2017 - 2030 (USD Million)
12. Competitive Landscape
13. Key Vendor Analysis
14. Hepatitis B Vaccine Market Cost Analysis
15. Industrial Chain, Sourcing Strategy and Downstream Buyers
16. Marketing Strategy Analysis, Distributors/Traders
17. Market Effect Factors Analysis
18. Future Outlook of the Market

𝗥𝗲𝗮𝗱 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝗜𝗻𝗱𝗲𝘅 𝗼𝗳 𝗳𝘂𝗹𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝘁𝘂𝗱𝘆 𝗮𝘁
https://www.contrivedatuminsights.com/product-report/hepatitis-b-vaccine-market-248514

𝗪𝗵𝘆 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗕𝘂𝘆 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁:
1. The forecast for the established and growing markets for global Hepatitis B Vaccine Market.
2. Use Porter's Five Forces analysis to analyze various market perspectives.
3. The market segment that is anticipated to dominate the Hepatitis B Vaccine industry worldwide.
4. Geographical areas that are anticipated to experience the quickest growth over the projection period.
5. Identify the most recent innovations, market shares for global Hepatitis B Vaccine and marketing techniques used by the leading industry competitors.

𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗦𝗼𝘂𝗿𝗰𝗲:
False Eyelashes Market- https://www.digitaljournal.com/pr/news/global-false-eyelashes-market-is-estimated-to-grow-at-a-cagr-of-6-2-from-2023-to-2030
Mobility as a Service Market- https://www.digitaljournal.com/pr/news/global-mobility-as-a-service-market-is-projected-to-grow-at-a-cagr-of-18-5-during-the-forecast-period
Human Hair Extension Market- https://www.digitaljournal.com/pr/news/global-human-hair-extension-market-is-anticipated-to-grow-at-a-cagr-of-9-44-during-the-forecast-period
Pharmaceutical Packaging Market- https://www.digitaljournal.com/pr/news/global-pharmaceutical-packaging-market-is-forecasted-to-grow-at-a-cagr-of-5-8-during-the-forecast-period
Disposable Hygiene Products Market- https://www.digitaljournal.com/pr/news/global-disposable-hygiene-products-market-is-projected-to-grow-at-a-cagr-of-6-7-during-the-forecast-period
Robotic Air Purifier Market- https://www.digitaljournal.com/pr/news/global-robotic-air-purifier-market-is-anticipated-to-grow-at-a-cagr-of-8-5-during-the-forecast-period

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Anna B. | Head Of Sales
Contrive Datum Insights
Phone: +91 9834816757 | +1 2152974078
Email: anna@contrivedatuminsights.com

𝗔𝗯𝗼𝘂𝘁 𝗨𝘀:
Contrive Datum Insights (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology, telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives, and IT professionals to undertake statistics-based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country-level expertise.

This release was published on openPR.